Tropical diseases

Co-Diagnostics Plans Product Launch for Emerging Mosquito Threat EEE Virus as Demand Grows

Retrieved on: 
Wednesday, October 16, 2019
Infectious diseases, Medical specialties, Medicine, Neglected diseases, Tropical diseases, RTT, Zika virus, Zika fever, Chikungunya, Dengue fever, Mosquito

When their initial NAM-w product launched on July 11, CODX became one of the hottest tickers of the day and traded up 44% on substantial volume.

Key Points: 
  • When their initial NAM-w product launched on July 11, CODX became one of the hottest tickers of the day and traded up 44% on substantial volume.
  • That product was described as being created following requests from mosquito abatement districts and ministries of healthfor a test that can accurately identify Zika, dengue and chikungunya, but which is tailored specifically for mosquito populations.
  • And unlike in vitro diagnostics for humans, testing mosquito populations requires no regulatory approval by the FDA.
  • If the interest shown by analysts and followers of the stock is any indication, the launch of their EEE test should portend great things for this Utah-based medtech company.

Global West Nile Virus Therapeutics Market 2019-2023 | Evolving Opportunities With Aurobindo Pharma Ltd. and Bayer AG | Technavio

Retrieved on: 
Tuesday, October 8, 2019
Biotechnology, Pharmaceutical, Health, Infectious diseases, Medical specialties, Animal diseases, Tropical diseases, Flaviviruses, Zoonoses, RTT, West Nile

View the full release here: https://www.businesswire.com/news/home/20191008005557/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191008005557/en/
    Technavio has announced its latest market research report titled global West Nile Virus therapeutics market 2019-2023.
  • Also, rising awareness is anticipated to further boost the growth of the West Nile Virus therapeutics market.
  • West Nile Virus infection does not have a specific drug or vaccine that is approved or ideal for patients.
  • These benefits boost patient adherence and will drive the growth of the West Nile Virus therapeutics market during the forecast period.

Sabin Vaccine Institute Receives $20.5 Million From BARDA With Potential of up to $128 Million to Develop Ebola Sudan and Marburg Vaccines

Retrieved on: 
Tuesday, October 1, 2019
Infectious diseases, Animal diseases, Medicine, Ebola, Biological weapons, Tropical diseases, Zoonoses, Vaccine, Ebola virus disease, Zaire ebolavirus, Virus

Under the terms of this agreement, the full program is expected to advance development of clinical-stage monovalent vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials.

Key Points: 
  • Under the terms of this agreement, the full program is expected to advance development of clinical-stage monovalent vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials.
  • The BARDA funding will enable Sabin to advance the investigational Ebola Sudan and Marburg vaccines using the ChAd3-based platform recently licensed under an agreement between GSK and Sabin.
  • In August 2019, GSK and Sabin entered agreements for Sabin to advance the development of the prophylactic candidate vaccines against Ebola Zaire, Ebola Sudan and Marburg viruses.
  • Under the agreements, Sabin exclusively licensed the technology for all three candidate vaccines and acquired certain patent rights specific to these vaccines.

Dengue Outbreak in Southeast Asia Set to Increase Mosquito Control Insecticide Sales, Sees Kline

Retrieved on: 
Wednesday, September 25, 2019
Infectious diseases, Medical specialties, Medicine, Tropical diseases, Culicidae, Insect control, Epidemiology, Mosquito control, Mosquito, Dengue fever, Dengue outbreak in Singapore

In 2019, another disease outbreak is anticipated, as many Southeast Asian countries have reported a higher incidence of Dengue fever.

Key Points: 
  • In 2019, another disease outbreak is anticipated, as many Southeast Asian countries have reported a higher incidence of Dengue fever.
  • Insecticide sales for mosquito control are evaluated to be USD 200 million from seven major countries, including these four in Southeast Asia, as profiled in Kline's just published Mosquito Control: Global Market Analysis and Opportunities study.
  • Mosquito control programs are typically budgeted as part of a country's national healthcare plan and implemented by state or city municipal departments.
  • Bacterial-based products have already become a key ingredient in the U.S. mosquito control market, accounting for 15% of its total sales.

NewLink Genetics Announces FDA Accepts Partnered Biologics License Application (BLA) and Grants Priority Review for Ebola Vaccine V920 (rVSV∆G-ZEBOV-GP)

Retrieved on: 
Tuesday, September 17, 2019
Infectious diseases, Medicine, Medical specialties, Ebola, Biological weapons, Tropical diseases, Zoonoses, Ebola vaccine, Ebola virus disease, Food and Drug Administration, Zaire ebolavirus, Priority review

AMES, Iowa, Sept. 17, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mercks Biologics License Application (BLA) and granted priority review for the investigational Ebola vaccine (V920), for the prevention of disease caused by the Ebola Zaire virus.

Key Points: 
  • AMES, Iowa, Sept. 17, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mercks Biologics License Application (BLA) and granted priority review for the investigational Ebola vaccine (V920), for the prevention of disease caused by the Ebola Zaire virus.
  • As NewLink has previously stated, the FDAs approval of this Ebola vaccine would trigger the issuance of a priority review voucher owned by Merck and in which NewLink Genetics has a substantial economic interest.
  • Thereafter, NewLink would have the right to monetize its share of interest in the voucher.This Ebola vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC) and thereafter licensed to NewLink Genetics.
  • The forward-looking statements in this press release represent NewLink Genetics views as of the date of this press release.

FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus

Retrieved on: 
Tuesday, September 17, 2019
Health, FDA, Infectious diseases, Other Health, General Health, Medicine, Infectious diseases, Animal diseases, Ebola, West African Ebola virus epidemic, Biological weapons, Tropical diseases, Ebola vaccine, Zaire ebolavirus, Ebola virus disease, Food and Drug Administration, Biologics license application, Merck’s Investigational V920 Ebola Zaire Vaccine, Merck

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted priority review for Mercks investigational Ebola vaccine (V920), under review for the prevention of disease caused by the Ebola Zaire virus.

Key Points: 
  • Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted priority review for Mercks investigational Ebola vaccine (V920), under review for the prevention of disease caused by the Ebola Zaire virus.
  • Merck has worked with government partners and the global health community to accelerate development of our investigational V920 Ebola vaccine.
  • We look forward to continuing to work with the FDA throughout the review process.
  • Since May 2018, Merck has donated and shipped more than 245,000 1.0mL investigational V920 Ebola vaccine doses to the World Health Organization (WHO) in response to requests by the WHO.

Yemen eliminates lymphatic filariasis (elephantiasis)

Retrieved on: 
Wednesday, September 4, 2019
Infectious diseases, Medicine, Medical specialties, Tropical diseases, Neglected diseases, RTT, Spirurida, Lymphatic filariasis, Helminthiases, Filariasis, Elephantiasis, Lymphatic system

SANA'A, Yemen, Sept. 4, 2019 /PRNewswire/ -- MSD (trade name of Merck & Co., Inc., Kenilworth, N.J., USA), GSK, and the Mectizan Donation Program congratulate the government, and the people of Yemen for receiving validation by the World Health Organization (WHO) for eliminating lymphatic filariasis as a public health problem.

Key Points: 
  • SANA'A, Yemen, Sept. 4, 2019 /PRNewswire/ -- MSD (trade name of Merck & Co., Inc., Kenilworth, N.J., USA), GSK, and the Mectizan Donation Program congratulate the government, and the people of Yemen for receiving validation by the World Health Organization (WHO) for eliminating lymphatic filariasis as a public health problem.
  • Lymphatic filariasis (LF), commonly known as elephantiasis, is a debilitating disease caused by a parasite transmitted to humans through the bites of mosquitoes.
  • Long-term, chronic infection causes damage to the lymphatic system, and severe and irreversible swelling to the limbs, breasts, and/or genitals.
  • "Lymphatic filariasis is a debilitating, but preventable disease that affects individuals, families and communities.

GeoVax Announces Publication of Lassa Fever Vaccine Study Results

Retrieved on: 
Wednesday, September 4, 2019
Infectious diseases, Medicine, Animal diseases, Tropical diseases, Biological weapons, Zoonoses, Viral hemorrhagic fever, Ebola virus disease, Marburg virus disease, Zaire ebolavirus, Sudan virus, Modified vaccinia Ankara

GeoVaxs Lassa fever vaccine (GEO-LM01) is based on the Companys novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated.

Key Points: 
  • GeoVaxs Lassa fever vaccine (GEO-LM01) is based on the Companys novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated.
  • Lassa fever surpasses Ebola, Marburg, and all other hemorrhagic fevers except Dengue in its public health impact.
  • GEO-LM01 is one component of a multivalent hemorrhagic fever virus vaccine being developed by GeoVax.
  • The other vaccine components are for protection against Sudan virus (SUDV), Marburg virus (MARV), and Ebola virus (EBOV).

U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea

Retrieved on: 
Wednesday, September 4, 2019
Bacteria, Medical specialties, Branches of biology, Vibrionales, Gram-negative bacteria, Bacteriology, Neglected diseases, Tropical diseases, Vibrio, Antibody, Antigen, Shigella

The goal was to investigate the breadth of Travelans immunological reactivity against pathogenic Vibrio cholera bacterial isolates.

Key Points: 
  • The goal was to investigate the breadth of Travelans immunological reactivity against pathogenic Vibrio cholera bacterial isolates.
  • The ability of Travelan to bind these bacteria highlights the broad-spectrum recognition by Travelan of surface antigens on potentially debilitating and even life-threatening bacteria.
  • Last year we reported that the antibodies in Travelan bound to 180 different isolates of Campylobacter spp, ETEC, and Shigella spp.
  • The current study adds an additional 71 different clinical isolates of Vibrio cholera to the list.

SC Johnson Spatial Repellent Innovation Provides New Potential Solution for Communities in Malaria-Endemic Areas

Retrieved on: 
Thursday, August 29, 2019
Infectious diseases, Medical specialties, Medicine, Tropical diseases, RTT, Vaccine-preventable diseases, Dengue fever, Zika virus, Mosquito-borne disease, Malaria, Zika fever, Mosquito

The program is investigating the potential impact of spatial repellents in reducing mosquito-borne diseases like malaria, Zika and dengue fever.

Key Points: 
  • The program is investigating the potential impact of spatial repellents in reducing mosquito-borne diseases like malaria, Zika and dengue fever.
  • It's heartening that this week's WHO report shows spatial repellents could be an effective tool against the disease," said Fisk Johnson, Ph.D., Chairman and CEO of SC Johnson.
  • Researchers tested the efficacy of an innovative spatial repellent product, developed exclusively by SC Johnson, to reduce the transmission of malaria.
  • "There is a great team at SC Johnson dedicated to developing real-world solutions for this serious public health issue."